Moderna: increased Covid market share in the USA
The biotech company reiterates its objectives of product sales of around $4 billion in 2024, a return to growth in 2025 and break-even in 2026 thanks to disciplined product launches and investments.
"We are preparing for the launch of Moderna's second product, our RSV vaccine", emphasizes CEO Stéphane Bancel, who expects "an exciting 2024, with multiple milestones in our nine late-stage programs".
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction